Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial
Brief Description Of Study
POINT is a randomized, double-blind, multicenter trial that aims to determine whether clopidogrel 75 mg/day by mouth after a loading dose of 600 mg of clopidogrel is effective in preventing major ischemic vascular events (ischemic stroke, myocardial infarction, and ischemic vascular death) at 90 days when subjects are randomized within 12 hours of time last known free of new ischemic symptoms in patients receiving aspirin 50-325 mg/day. Patients 18 years of age or older with high-risk TIA (defined as an ABCD2 score greater than or equal to 4) or minor ischemic stroke (with NIHSS less than or equal to 3), who can be randomized within 12 hours of time last known free of new ischemic symptoms, will be enrolled. A total of 5,840 patients will be recruited. Each subject is followed for up to 150 days from randomization.